Pharnext
Develops therapies for neurodegenerative diseases by combining existing drugs.
ALPHA | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- FR0011191287 (+4 more)
- LEI:
- 969500KJGF9ZUYXSMJ27
- Country:
- France
- Address:
- 9 RUE DES FILLES SAINT-THOMAS, 75002 PARIS
- Website:
- https://pharnext.com/
- Sector:
- Manufacturing
Description
Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-27 13:00 |
Ouverture d'une procédure de liquidation judiciaire
|
French | 194.1 KB | ||
| 2024-08-01 18:00 |
Ajustement de la valeur nominale
|
French | 189.9 KB | ||
| 2024-07-18 18:00 |
Point concernant l'accord de financement en obligations convertibles accordé pa…
|
French | 194.2 KB | ||
| 2024-07-15 18:00 |
Demande d'ouverture d'une procédure de liquidation judiciaire
|
French | 193.2 KB | ||
| 2024-07-10 08:00 |
Pharnext fait un point sur sa situation financière
|
French | 191.6 KB | ||
| 2024-07-04 20:00 |
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
|
French | 232.3 KB | ||
| 2024-07-03 08:00 |
Pharnext fait un point sur les conséquences de sa situation stratégique et fina…
|
French | 208.2 KB | ||
| 2024-07-01 18:30 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 185.7 KB | ||
| 2024-06-28 08:00 |
Pharnext fait un point d'étape sur les dernières avancées majeures d'un point d…
|
French | 209.3 KB | ||
| 2024-06-18 18:30 |
Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 jui…
|
French | 194.9 KB | ||
| 2024-06-05 18:30 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 181.3 KB | ||
| 2024-05-29 18:00 |
Ajustement de la valeur nominale
|
French | 190.9 KB | ||
| 2024-05-07 19:10 |
Ajustement de la valeur nominale
|
French | 190.6 KB | ||
| 2024-05-06 18:00 |
Pharnext convoque ses actionnaires en assemblée générale le 10 juin 2024
|
French | 194.7 KB | ||
| 2024-05-02 18:30 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 195.4 KB |
Automate Your Workflow. Get a real-time feed of all Pharnext filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharnext
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharnext via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}